Buchumschlag

Acetazolamide reduces the erythropoietin response to hypoxia at high altitude in humans

Objective - Acetazolamide, a carbonic anhydrase inhibitor, is often used as a prophylactic drug for acute mountain sickness. It may interfere with erythropoietin production due to its action on ventilation and renal function. - Design - A randomized, double-blind, placebo-controlled trial with 2×250...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Reinhart, Walter H. (VerfasserIn) , Goerre, Stefan (VerfasserIn) , Bärtsch, Peter (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 1994
In: Wilderness & environmental medicine
Year: 1994, Jahrgang: 5, Heft: 3, Pages: 312-317
ISSN:1545-1534
DOI:10.1580/0953-9859-5.3.312
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1580/0953-9859-5.3.312
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S095398599471130X
Volltext
Verfasserangaben:Walter H. Reinhart, Stefan Goerre, Peter Bärtsch
Beschreibung
Zusammenfassung:Objective - Acetazolamide, a carbonic anhydrase inhibitor, is often used as a prophylactic drug for acute mountain sickness. It may interfere with erythropoietin production due to its action on ventilation and renal function. - Design - A randomized, double-blind, placebo-controlled trial with 2×250mg acetazolamide daily beginning one day before ascent from 590 m to 4559 m. - Setting - High-altitude research facilities at the Capanna Regina Margherita (Italy) at an altitude of 4559 m. - Participants - Eighteen healthy volunteers, aged 24-42 years. Main outcome measure: Plasma erythropoietin was measured by radioimmunoassay before and after the ascent. - Results - The increase of erythropoietin at high altitude was smaller in the acetazolamide group (increase by 10.8±7.8 U/L or 58%) than in the placebo group (increase by 22.7±13.8 U/L or 113%, p<.01). - Conclusion - Acetazolamide reduces the erythropoietin response to hypoxia in humans, which might also have therapeutic implications in conditions such as secondary polycythemia.
Beschreibung:Elektronische Reproduktion der Druck-Ausgabe 12. April 2010
Gesehen am 22.01.2024
Beschreibung:Online Resource
ISSN:1545-1534
DOI:10.1580/0953-9859-5.3.312

Ähnliche Einträge